As Cyclospora Cases Climb, FDA Official Says Food Supply Is Safe
Julie Creswell / nytimes - The acting deputy commissioner for food said the agency was taking action even though finding the root cause of the outbreaks is difficult.
AI Summary: Health authorities are tracking a rising number of cyclospora infections while stressing the overall safety of the food supply. Officials urged vigilance and proper food handling, noting some patients experience severe gastrointestinal illness. Public health experts warned that recurring outbreaks raise concerns about vulnerabilities in produce safety and monitoring systems.
- Iceberg lettuce link: multistate traceback and restaurant impacts (4)
- Public health strain: FDA reassures, experts warn, symptoms and travel (5)
- Scope and toll: exploding cases, hospitalizations and first U.S. deaths (6)
- All Other Stories
Iceberg lettuce link: multistate traceback and restaurant impacts
Public health strain: FDA reassures, experts warn, symptoms and travel
Scope and toll: exploding cases, hospitalizations and first U.S. deaths
All Other Stories
Centene boosts guidance amid $1.1B Q2 profit, ACA membership drop
Elizabeth Casolo / beckershospitalreview - Centene brought in a $1.1 billion profit for the second quarter of 2026, up from a $253 million loss at the same time last year, according to the company’s July 28 earnings report. Total revenue approached $53.6 billion for the quarter, up nearly 10% year…
AI Summary: Centene reported a dramatic Q2 turnaround, posting about $1.1 billion in profit and raising its 2026 guidance despite an ACA membership decline. Executives credited improved margins and operational adjustments for the rebound, signaling a healthier financial posture as the company navigates policy and enrollment headwinds.
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.